Almirall (ALM) AI Stock Analysis

• Market Cap: €2.78B
• Dividend Yield: 1.22%
• Average Volume (3M): 106.20K
• Price to Earnings (P/E): 129.6
• Beta (1Y): 0.51
• Revenue Growth: 13.32%
• EPS Growth: N/A
• Country: ES
• Employees: 2,026
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 0.13
• Shares Outstanding: 214,785,200
• 10 Day Avg. Volume: 134,753
• 30 Day Avg. Volume: 106,204
• PEG Ratio: -1.38
• Price to Book (P/B): 1.17
• Price to Sales (P/S): 1.77
• P/FCF Ratio: -2.62K
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: €13.90
• Price Target Upside: 7.75% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 60 Neutral
• Price Target: €13.50 ▲(4.65% Upside)

Almirall's overall stock score is primarily influenced by its stable financial position and positive technical indicators. However, the high P/E ratio and low net profitability weigh down the score. The absence of recent earnings call data and corporate events limits additional insights.

Positive Factors

Strong Gross Margins

Strong gross margins indicate effective cost control and pricing power, supporting long-term profitability and competitiveness in the pharmaceutical industry.

Stable Financial Position

A stable financial position with manageable debt levels provides Almirall with the flexibility to invest in growth opportunities and withstand economic fluctuations.

Revenue Growth

Consistent revenue growth, even if moderate, suggests a resilient demand for Almirall's products and the potential for future expansion in its core markets.

Negative Factors

Low Net Profit Margins

Low net profit margins indicate challenges in translating revenue into profit, which could hinder the company's ability to reinvest in growth and reward shareholders.

Negative Free Cash Flow Growth

Negative free cash flow growth suggests cash constraints, potentially limiting Almirall's capacity to fund new projects and meet financial obligations without external financing.

Low Return on Equity

Low return on equity indicates inefficiency in generating profits from shareholder investments, which may affect investor confidence and the company's ability to attract new capital.

Almirall Business Overview & Revenue Model

Company Description

Almirall (ALM) is a global pharmaceutical company headquartered in Barcelona, Spain, specializing in the research, development, and commercialization of innovative dermatological products. The company operates primarily in the dermatology and respiratory sectors, offering a range of prescription medicines, over-the-counter products, and medical devices. Almirall's core portfolio includes treatments for skin conditions such as psoriasis, atopic dermatitis, and acne, along with products aimed at chronic obstructive pulmonary disease (COPD).

How the Company Makes Money

Almirall generates revenue primarily through the sale of its pharmaceutical products across various markets. The company’s revenue model is based on direct sales of its proprietary drugs, which include a mix of branded medications and generics. Key revenue streams also come from partnerships and collaborations with other pharmaceutical companies, which may involve co-development and licensing agreements for specific products. Additionally, Almirall invests in research and development to expand its product portfolio, which can lead to new market opportunities and increased sales. The company’s ability to innovate and respond to market demands, along with maintaining strategic partnerships, significantly contributes to its earnings.

Almirall Financial Statement Overview

Summary

Almirall exhibits a stable financial position with strong gross margins and manageable debt levels. However, profitability remains a concern with low net profit margins and negative free cash flow growth. The company needs to focus on improving cash flow generation and enhancing shareholder returns to strengthen its financial health.

Income Statement

Almirall's income statement shows moderate growth and profitability. The TTM revenue growth rate of 2.54% indicates steady progress, although it has slowed compared to previous years. Gross profit margins remain strong at 78.09%, reflecting efficient cost management. However, net profit margins are low at 2.03%, suggesting limited profitability. The EBIT and EBITDA margins are improving, indicating better operational efficiency.

Balance Sheet

The balance sheet reflects a stable financial position with a debt-to-equity ratio of 0.28, indicating manageable leverage. The return on equity is low at 1.44%, suggesting limited returns for shareholders. The equity ratio of 63.41% demonstrates a solid capital structure with a significant portion of assets financed by equity.

Cash Flow

Cash flow analysis reveals challenges, with negative free cash flow growth of -18.03% in the TTM period. The operating cash flow to net income ratio of 0.51 indicates moderate cash generation relative to net income. However, the negative free cash flow to net income ratio highlights cash flow constraints, potentially impacting future investments.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	1.08B	985.72M	894.52M	863.25M	827.20M	1.61B
Gross Profit	829.28M	767.68M	577.12M	680.78M	655.61M	1.44B
EBITDA	225.40M	173.80M	114.33M	157.01M	132.34M	213.35M
Net Income	42.05M	10.15M	-38.47M	4.28M	-40.86M	74.28M
Balance Sheet
Total Assets	2.36B	2.40B	2.37B	2.15B	2.14B	2.29B
Cash, Cash Equivalents and Short-Term Investments	376.60M	377.30M	388.09M	248.82M	207.39M	165.67M
Total Debt	337.10M	408.81M	403.25M	403.88M	396.11M	496.98M
Total Liabilities	882.40M	908.28M	911.59M	828.98M	855.71M	988.15M
Stockholders Equity	1.48B	1.49B	1.46B	1.32B	1.29B	1.30B
Cash Flow
Free Cash Flow	29.94M	-664.00K	-65.82M	38.62M	162.70M	88.24M
Operating Cash Flow	200.97M	160.77M	93.48M	155.10M	233.85M	164.76M
Investing Cash Flow	-120.24M	-140.04M	-122.56M	-68.54M	-57.26M	-75.52M
Financing Cash Flow	-51.51M	-31.58M	168.21M	-45.12M	-134.88M	-40.87M

Almirall Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 12.90
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ES:ALM, the sentiment is Positive. The current price of 12.9 is above the 20-day moving average (MA) of 12.88, above the 50-day MA of 12.49, and above the 200-day MA of 11.07, indicating a bullish trend. The MACD of 0.16 indicates Positive momentum. The RSI at 56.58 is Neutral, neither overbought nor oversold. The STOCH value of 34.21 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ES:ALM.

Almirall Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
FAE	78 Outperform	€1.55B	14.69	14.89%	3.60%	11.04%	8.29%
ROVI	74 Outperform	€3.14B	26.22	20.70%	1.51%	-9.39%	-25.92%
RJF	65 Neutral	€217.25M	48.81	2.03%	1.84%	-1.19%	-54.66%
ALM	60 Neutral	€2.78B	129.60	1.45%	1.22%	13.32%	―
PHM	57 Neutral	€1.36B	39.50	17.22%	1.05%	7.35%	5375.64%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%